Summary of declared interests

Name

Designation

Interests

Decision

Lisa Bero

University of California, San Francisco

Editor of Cochrane Collaboration Review Group Effective Practice & Organization of Care, of which some reviews relate to pricing policy. Editor position is unpaid.

No further action required

Sudip Chaudhuri

Indian Institute of Management, Calcutta

Study for United Nations Development Programme of industry response to product patent regime in India.
Involved in a research project on non-government action to improve the poor's access to quality, cheap medicines. Economic and Social Research Council, UK.
United Nations Industrial Development Organization project on local production in Ghana (on-going).

No further action required

Mari Mathiesen

Estonian Health Insurance Fund

Provision/approval of expert opinion to state institutions related to the subject of the guideline as part of current employment at Estonian Health Insurance Fund.
Married to a person actively involved in pharmaceutical consultancy business in Estonia (mainly regulatory and pre-marketing services to pharmaceutical manufacturers).

No further action required

Jaime Espin Balbino

Andalusia School of Public Health (EASP)

EASP sponsorship and training – Eli Lilly, Sanofi-Aventis, Chiesi, Pfizer.
Various honoraria for speaking on economic evaluation, pharmaceutical policies, risk sharing agreements, sponsored by Sanofi-Aventis, Novartis, Eli Lilly, Chiesi, Merck.

No further action required

Prashant Yadav

MIT-Zaragoza International Logistics Centre

Research or consulting directly related to the work:

Principal investigator for research on differential pricing sponsored by UK Department for International Development.
External expert, differential pricing meeting, GlaxoSmithKline.
WHO/Government of India/Centre for Trade & Development workshop on pharmaceutical pricing.

Other relevant disclosures:

Postgraduate students carried out research on pharmaceutical distribution in Africa, funded by Pfizer.
Assisted in a national Malaria Control Program Managers Best Practices Sharing seminar in Zambia funded by Novartis.
Presented “Multiple First Line Treatments for Malaria: Challenges and Opportunities” at conference of the Multi-lateral Initiative on Malaria in Kenya, sponsored by Pfizer.
Helped conduct a National Malaria Control Program Managers Best Practices Sharing seminar in Rwanda, sponsored by Novartis.

Testimony/public address related to guideline:

Driving Malaria Reduction Globally: the role of supply chains, Congressional briefing, Washington, DC, USA.
Briefing on differential pricing of pharmaceuticals, the Industry Forum on Access to Medicines, London, UK.

No further action required

Fatima Suleman

University of Kwazulu-Natal

Member of pricing committee, Department of Health, South Africa.
Postgraduate bursaries for drug development and pharmacoeconomics awarded to the School of Pharmacy and Pharmacology by Aspen and Merck Foundation.
Travel to attend and present at a conference on pharmacy practice in New Zealand sponsored by Pfizer.

No further action required

Sauwakon Ratanawijitrasin

Mahidol University

Participated in a meeting as a pharmaceutical policy expert, Novartis and AstraZeneca.

No further action required

Thamizhanban Pillay

Health Financing and Economics Cluster, National Department of Health, South Africa

Wife employed as a clinical research associate with Roche.
Public statements.
Outcome of meeting could benefit government.

No further action required

Suzanne Hill

Department Health and Aging, Australia

Current position as Chair of the Australian Pharmaceutical Benefits Advisory Committee is a full paid position by the Australian Department of Health and requires public statements including pricing policy advice for the Australian Government.

No further action required

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

Bookshelf ID: NBK258627

Contents

< Prev Next >

Bookshelf

WHO Guideline on Country Pharmaceutical Pricing Policies.

9.3 Annex CSummary of declared interests

Annex Box 3Declared interests of panel

Views

Other titles in this collection

Recent Activity

Name	Designation	Interests	Decision
Lisa Bero	University of California, San Francisco	Editor of Cochrane Collaboration Review Group Effective Practice & Organization of Care, of which some reviews relate to pricing policy. Editor position is unpaid.	No further action required
Sudip Chaudhuri	Indian Institute of Management, Calcutta	Study for United Nations Development Programme of industry response to product patent regime in India. Involved in a research project on non-government action to improve the poor's access to quality, cheap medicines. Economic and Social Research Council, UK. United Nations Industrial Development Organization project on local production in Ghana (on-going).	No further action required
Mari Mathiesen	Estonian Health Insurance Fund	Provision/approval of expert opinion to state institutions related to the subject of the guideline as part of current employment at Estonian Health Insurance Fund. Married to a person actively involved in pharmaceutical consultancy business in Estonia (mainly regulatory and pre-marketing services to pharmaceutical manufacturers).	No further action required
Jaime Espin Balbino	Andalusia School of Public Health (EASP)	EASP sponsorship and training – Eli Lilly, Sanofi-Aventis, Chiesi, Pfizer. Various honoraria for speaking on economic evaluation, pharmaceutical policies, risk sharing agreements, sponsored by Sanofi-Aventis, Novartis, Eli Lilly, Chiesi, Merck.	No further action required
Prashant Yadav	MIT-Zaragoza International Logistics Centre	Research or consulting directly related to the work: Principal investigator for research on differential pricing sponsored by UK Department for International Development. External expert, differential pricing meeting, GlaxoSmithKline. WHO/Government of India/Centre for Trade & Development workshop on pharmaceutical pricing. Other relevant disclosures: Postgraduate students carried out research on pharmaceutical distribution in Africa, funded by Pfizer. Assisted in a national Malaria Control Program Managers Best Practices Sharing seminar in Zambia funded by Novartis. Presented “Multiple First Line Treatments for Malaria: Challenges and Opportunities” at conference of the Multi-lateral Initiative on Malaria in Kenya, sponsored by Pfizer. Helped conduct a National Malaria Control Program Managers Best Practices Sharing seminar in Rwanda, sponsored by Novartis. Testimony/public address related to guideline: Driving Malaria Reduction Globally: the role of supply chains, Congressional briefing, Washington, DC, USA. Briefing on differential pricing of pharmaceuticals, the Industry Forum on Access to Medicines, London, UK.	No further action required
Fatima Suleman	University of Kwazulu-Natal	Member of pricing committee, Department of Health, South Africa. Postgraduate bursaries for drug development and pharmacoeconomics awarded to the School of Pharmacy and Pharmacology by Aspen and Merck Foundation. Travel to attend and present at a conference on pharmacy practice in New Zealand sponsored by Pfizer.	No further action required
Sauwakon Ratanawijitrasin	Mahidol University	Participated in a meeting as a pharmaceutical policy expert, Novartis and AstraZeneca.	No further action required
Thamizhanban Pillay	Health Financing and Economics Cluster, National Department of Health, South Africa	Wife employed as a clinical research associate with Roche. Public statements. Outcome of meeting could benefit government.	No further action required
Suzanne Hill	Department Health and Aging, Australia	Current position as Chair of the Australian Pharmaceutical Benefits Advisory Committee is a full paid position by the Australian Department of Health and requires public statements including pricing policy advice for the Australian Government.	No further action required